Research programme: TGF-beta oligonucleotide nanoparticles - Capsulution Pharma

Drug Profile

Research programme: TGF-beta oligonucleotide nanoparticles - Capsulution Pharma

Alternative Names: TGF-B antisense oligonucleotides - NanoDel; TGF-beta antisense oligonucleotides - NanoDel

Latest Information Update: 18 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoDel Technologies
  • Developer Capsulution Pharma
  • Class Antisense oligonucleotides
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain cancer

Most Recent Events

  • 18 May 2011 No development reported - Preclinical for Brain cancer in Germany (unspecified route)
  • 17 Aug 2005 Preclinical trials in Brain cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top